Atıf İçin Kopyala
Yamazhan T., TURAN İ., Ersoz G., Gunsar F., Pullukcu H., Danis N., ...Daha Fazla
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.31, sa.3, ss.239-246, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
31
Sayı:
3
-
Basım Tarihi:
2020
-
Doi Numarası:
10.5152/tjg.2020.19076
-
Dergi Adı:
TURKISH JOURNAL OF GASTROENTEROLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.239-246
-
Anahtar Kelimeler:
Ledipasvir, Turkey, sofosbuvir, chronic hepatitis C, effectiveness, safety, ADVANCED LIVER-DISEASE, GENOTYPE 1, WORLD EFFECTIVENESS, PLUS RIBAVIRIN, RISK-FACTORS, HCV, LEDIPASVIR/SOFOSBUVIR, MULTICENTER, INFECTIONS
-
Dokuz Eylül Üniversitesi Adresli:
Hayır
Özet
Background/Aims: Ledipasvir (LDV) and sofosbuvir (SOF) as single-tablet regimen (STR) has been approved for treatment of chronic HCV infection (CHC) for treatment-naive or experienced cirrhotic or non-cirrhotic patients. Our aim was to analyse the effectiveness and safety of 12-24 weeks treatment of LDV/SOF (90mg/400 mg)+/- ribavirin in a real-life setting in Turkey.